Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	5/18/1954
Sex:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	01/01/2017 12:34

Carisoprodol Urine with Reflex to Quantitation

ARUP test code 2012278

Carisoprodol Screen, Urine	PresumptivePOS ng/mL * Presumptive positive results are automatically reflexed to confirmation testing by mass spectrometry. INTERPRETIVE INFORMATION: Carisoprodol Screen, Urine Methodology: Immunoassay Positive Cutoff: 100 ng/mL This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.
Screen, Urine Interpretation	See Note INTERPRETIVE INFORMATION: Flagging indicates a positive result; not that the result is abnormal. Presumptive negative results for drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. For medical purposes only; not valid for forensic use.

Carisoprodol and Meprobamate, Urine, Quantitative

ARUP test code 2012219

Carisoprodol, Urn, Quant	<100.0 ng/mL INTERPRETIVE INFORMATION: Carisoprodol and Met, Urine, Quant Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry Positive cutoff: Carisoprodol 100 ng/mL Meprobamate 100 ng/mL

H=High, L=Low, *=Abnormal, C=Critical

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug is common and may indicate use of parent drug during the prior week.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Meprobamate, Urn, Quant	>10000.0 ng/mL

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Carisoprodol Screen, Urine	25-196-403009	7/15/2025 12:01:00 AM	7/15/2025 5:52:09 PM	7/15/2025 7:04:00 PM
Screen, Urine Interpretation	25-196-403009	7/15/2025 12:01:00 AM	7/15/2025 5:52:09 PM	7/15/2025 7:04:00 PM
Carisoprodol, Urn, Quant	25-196-403009	7/15/2025 12:01:00 AM	7/15/2025 7:04:29 PM	7/15/2025 7:07:00 PM
Meprobamate, Urn, Quant	25-196-403009	7/15/2025 12:01:00 AM	7/15/2025 7:04:29 PM	7/15/2025 7:07:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical